Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2022, specifically dated February 2, 2022. The report details a significant corporate development involving ViiV Healthcare, GSK's majority-owned (78.3%) global specialist HIV company. The filing announces the resolution of global patent infringement litigation between ViiV Healthcare (along with shareholders GSK and Shionogi) and Gilead Sciences, Inc. regarding ViiV's dolutegravir patents and Gilead's HIV medicine, Biktarvy.
Key Financial Metrics and Transaction Details
- Upfront Payment: Gilead will pay ViiV Healthcare an upfront sum of $1.25 billion, expected in the first quarter of 2022.
- Royalty Agreement: Gilead will pay a 3% royalty on all future US sales of Biktarvy (which generated $6.09 billion in 2020) and on the bictegravir component of other future products sold in the US.
- Duration: Royalties are payable from February 1, 2022, until the expiry of ViiV's U.S. Patent No. 8,129,385 on October 5, 2027, excluding any regulatory pediatric exclusivity period.
- Accounting Treatment: The $1.25 billion upfront payment will be recorded as an adjusting item in GSK's Q1 2022 income statement. Future royalty income will be recorded in total and adjusted results for 2022 through 2027.
- Shareholder Distribution: Proceeds will be distributed based on shareholding (GSK 78.3%, Pfizer 11.7%, Shionogi 10%) net of contingent consideration liability (CCL) to Shionogi and applicable taxes.
Material Changes and Accounting Impacts
The settlement results in the discontinuation of patent infringement cases in the US, UK, France, Ireland, Germany, Japan, Korea, Australia, and Canada. A material accounting change involves the fair value of the contingent consideration liability (CCL) to Shionogi and the Pfizer put option. Both the settlement and future royalty income increase the fair value of these liabilities. The associated charges for these increases will be reflected in GSK's 2021 full-year and fourth-quarter results within adjusting items. Cash inflows from the settlement and royalties, and outflows from the CCL, will be recorded in cash generated from operations, while increased dividends to Shionogi and Pfizer will be included in financing cash flows.
Guidance, Outlook, and Risks
The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties, including those described in GSK's 2020 Annual Report on Form 20-F, 2021 Q3 Results, and the ongoing impacts of the COVID-19 pandemic. GSK explicitly states it undertakes no obligation to update these forward-looking statements. The settlement provides a clear revenue stream through 2027 but introduces accounting volatility in the 2021 results due to the revaluation of the CCL and put option.
Key Facts for Investor Verification
- Verify the exact timing of the $1.25 billion cash receipt in Q1 2022 financial statements.
- Confirm the specific charge amounts recorded in 2021 full-year and Q4 results related to the increased fair value of the CCL and Pfizer put option.
- Monitor future royalty payments based on Gilead's actual US sales of Biktarvy and other bictegravir-containing products.
- Review the impact of the settlement on the valuation of GSK's investment in ViiV Healthcare and the potential exercise of the Pfizer put option.